Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Pfizer expects to see drugs discovered and developed in Asia brought into the clinic in about three years, Pfizer's Pharma Therapeutics R&D Head Martin Mackay told local reporters April 7 during a press conference at the company's Clinical Research Unit at Raffles Hospital in Singapore
You may also be interested in...
Life After Pfizer: MicuRx Forms JV To Develop Antibiotics In China
The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.
Singapore’s Clinical Trials Registry May Attract Wider Patient Pool
The launch of a clinical trials registry in Singapore is another step in the wealthy city-state’s efforts to serve as a treatment hub in Asia for cutting-edge therapies.
South Korean Plan To Shorten IND Approvals Raises Competition With Singapore For Clinical Trials Hub
Patient differences will come into sharper relief in attracting Phase I clinical trials if, as expected, South Korea cuts its IND approval timeline near par with Singapore.